Whangārei And Counties Manukau To Receive 24/7 Urgent Care Boost
Minister of Health
Faster, more accessible urgent care for communities across Auckland and Northland will be delivered through Budget 2025, Health Minister Simeon Brown says.
'The Government is making a significant investment to improve access to urgent and after-hours healthcare nationwide, including across the Northern region,' Mr Brown says.
'Strengthening urgent and after-hours care is a key part of our plan to ensure all New Zealanders – including Aucklanders and Northlanders – can access timely, quality healthcare, when and where they need it.
'Budget 2025 will fund a new 24/7 urgent care service identified for Counties Manukau, providing more accessible after-hours options and easing pressure on the region's already busy emergency departments, including Middlemore.
'A new 24/7 urgent care service in Whangārei has also been identified, significantly improving access to care outside normal hours in Northland's largest city.'
Communities across Auckland and Northland will also benefit from extended opening hours, and greater support for rural and remote providers, with changes being rolled out over the next two years.
'These investments will give people – especially in rural and remote communities – greater access to essential services like diagnostics and urgent medicines when they need them.
'More options in the evening, overnight, and on weekends for locals will also reduce pressure on emergency departments and deliver better outcomes for patients.'
Key Budget 2025 initiatives for the Northern region include:
A new 24/7 urgent care service identified for Counties Manukau by late 2025.
A new 24/7 urgent care service identified for Whangārei from 2026.
Maintaining all existing urgent and after-hours healthcare services in the region.
Extended after-hour services identified for Dargaville, Hokianga, Kaitaia, and Wellsford.
Improved services for rural and remote Northland communities, including better access to diagnostics, urgent medicines, and 24/7 on-call clinical support.
'This Government is investing more in health than ever before, with a record $16.68 billion over three Budgets to improve health outcomes for Kiwis.
'Our investment will give Aucklanders and Northlanders more choice, reduce wait times, and bring care closer to home,' Mr Brown says.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Otago Daily Times
13 hours ago
- Otago Daily Times
Business case flawed: Brooking
The release of a "flawed" business case means more information is needed before Labour decides whether it would dump the planned Waikato Medical School, a Dunedin MP says. Last Monday, Health Minister Simeon Brown announced Cabinet had approved $82.85 million in government funding to build the country's third medical school at the University of Waikato — the institution was expected to contribute more than $150m to the project. Dunedin MP Rachel Brooking, of Labour, said she was "very sceptical" about figures used by the government to make its decision. The project's detailed business case was made public on Friday evening, part of a document dump which revealed the cost of producing GPs at the graduate-entry Waikato medical school would be $50 million a year cheaper than at the existing medical schools at Otago and Auckland universities. "The business case has really been written with an outcome in mind and not traversed all of the options, and that's just bad decision-making," Ms Brooking said. "It's bad way to make use of taxpayers' money, and it seems that in general, this all will cost more." She said the "flawed" business case would have consequences for the Otago Medical School: "those are difficult to predict exactly". However, Labour had "no plans at the moment" to dump the medical school, Ms Brooking said. "The issue is that we don't think the business case is credible. "So we'll keep asking questions about that and try and make any assessments on good information when we're in a position to do so." Taieri MP Ingrid Leary said "the so-called business case is really just a public relations document, given the outlandish assumptions and comparators". In a statement last Monday, Mr Brown said the project was an innovative model "that supports our focus on strengthening primary care, making it easier for people to see their doctor — helping Kiwis stay well and out of hospital". Waikato University would begin construction on new teaching facilities later this year. A full cost-benefit analysis was presented to Cabinet before any proposal was finalised, as part of the National-Act New Zealand coalition agreement, he said. Green MP Francisco Hernandez said the government's cost-benefit analysis used to "ram through" the Waikato Medical School made assumptions revealing the "lack of objectivity". Mr Hernandez said the document "falsely assumed" Otago and Auckland universities could not have negotiated a four-year rural graduate programme similar to Waikato University's proposal. "This assumption enables the government to claim that Waikato University will train medical students 'cheaper' because Waikato is assumed to have a four-year programme," he said. The government had also assumed Waikato University was more likely to produce GPs "even though Otago and Auckland could have also done a rural graduate programme". "Fundamentally, these flawed assumptions stem from the government's failure to run a transparent tender process from the start," Mr Hernandez said. "Rather than putting out an open tender to every university in New Zealand, they gave Waikato University a sweetheart deal." He called for the government to "be up front and honest about the actual costs" of the project and release the full agreement with Waikato University with all relevant advice. "The government's failure to rule out further handouts or to release the actual agreement raises questions on whether there were further sweetheart deals negotiated behind closed doors in the agreement that might end up with the taxpayer bailing out Waikato University."
RNZ News
2 days ago
- RNZ News
Hysteroscopy outpatient service at North Shore Hospital to speed up diagnosis
North Shore Hospital in Auckland. Photo: rafaelbenari/123RF A new outpatient hysteroscopy service at Auckland's North Shore Hospital will help gynaecological patients get a faster diagnosis. Health Minister Simeon Brown said it combines their first specialist assessment (FSA) and diagnostic procedure into a single visit. "This is a practical, patient-focused pathway that means women can get the answers they need sooner, without the stress and delays of multiple appointments or hospital admission," Brown said. A hysteroscopy is a procedure used to look inside the womb (uterus) and at the lining of the womb. A sample (biopsy) of the lining is usually taken as part of a diagnostic hysteroscopy, to look for abnormalities. Patients with symptoms such as abnormal vaginal bleeding, irregular periods and infertility might be referred for a hysteroscopy. "Previously, women needing a hysteroscopy would attend an initial specialist appointment and then wait weeks to undergo the procedure in theatre under general anaesthetic." Brown said the new approach removed that delay for women suitable for the treatment. "Now, women needing an uncomplicated hysteroscopy procedure can choose to have both the specialist assessment and the procedure in a single outpatient appointment. "That means fewer hospital visits, less time off work or away from family, and a much more streamlined experience. "For women with a high suspicion of cancer, this pathway can reduce the diagnostic timeline by two to six weeks compared to traditional models. That time could make all the difference." Health Minister Simeon Brown. Photo: RNZ / REECE BAKER North Shore Hospital expects to deliver around 60 outpatient hysteroscopy clinics over the next 12 months, with approximately 240 procedures. "Every outpatient procedure frees up valuable theatre space and clinical teams for patients who require more complex surgery. That's better for patients, and better for the whole system," Brown said. The new service meant a significant proportion of uncomplicated hysteroscopies that would have otherwise been performed in theatre under anaesthesia can now be done safely as outpatient procedures. "This is part of a regional effort to improve the quality, timeliness, and experience of care for women undergoing investigation for gynaecological cancers. "It will also play an important role in meeting our faster cancer treatment target by speeding up diagnosis and helping women start treatment sooner." The new service followed similar successful models already operating in Auckland, Counties Manukau, and Waikato. Sign up for Ngā Pitopito Kōrero , a daily newsletter curated by our editors and delivered straight to your inbox every weekday.
NZ Herald
2 days ago
- NZ Herald
Pharmac must shift from being a gatekeeper of cost to an enabler of health
Their tireless advocacy, amplified by journalist Rachel Smalley's sharp campaigning and the lived experiences of thousands of New Zealanders, has helped shift this conversation from the margins to the mainstream. The public mood is shifting. Pharmac, once internationally respected for its fiscal restraint, now faces growing pressure to demonstrate its relevance in a rapidly evolving healthcare environment. How Pharmac can transform into a health enabler: Cecilia Robinson writes that it's about reimagining what Pharmac is here to do. Photo / Getty Images The question is no longer whether Pharmac is doing the best it can with what it has, but whether its model is still fit for purpose. As someone who moved from Sweden, where access to modern treatments is standard, I was horrified to discover that many New Zealanders must turn to Givealittle to fund medicines available freely elsewhere. It's not just unfair. It's unthinkable. Therefore, the appointment of Natalie McMurtry as Pharmac's new chief executive comes at a critical time. While her background in Alberta's health system brings relevant experience, the task ahead is not just about leadership, it's about reimagining what Pharmac is here to do. Pharmac must shift from being a gatekeeper of cost to an enabler of health impact. Its role can no longer be confined to doing more with less. The public expects more transparency, compassion and to access medicines freely available in countries such as Australia, Ireland and Singapore. Pharmac's original model was developed in a different era, when the core challenge was controlling pharma companies, who were gaming the system, and skyrocketing costs. These issues are still important, but cost-effectiveness, particularly as measured through QALYs (Quality-Adjusted Life Years), is now too narrow a lens. It doesn't account for broader system benefits: medicines that prevent hospitalisation, help people stay in work, reduce caregiving pressure or support mental wellbeing. New Zealand's medicine gap persists despite a $604 million investment, with patient advocates urging change. Photo / 123rf We need to move towards a broader, health-impact framework. Medicines should not be viewed in isolation as a standalone budget line but as levers that can help to reduce pressure across the entire system. They reduce demand on emergency departments, improve quality of life and help address chronic conditions before they escalate. This evolution in thinking requires stronger alignment between Pharmac and Health New Zealand Te Whatu Ora. As integrated care becomes the national direction, the way we fund medicines must reflect how those medicines contribute to overall system efficiency and patient outcomes. Pharmac's current structure, operating within a ring-fenced budget, has created artificial constraints that limit innovation. While it has helped secure competitive prices, it has also locked us into a rigid, risk-averse model that can't keep pace with the demands of modern medicine. To stay relevant, Pharmac must adopt smarter, more flexible funding approaches. This includes: ● Outcomes-based pricing: linking funding to real-world results, so high-cost drugs are only paid for if they work ● 'Access equity' funding: targeted budgets for treatments that don't fit traditional metrics, such as rare disease therapies ● Public-private co-investment: partnerships to enable earlier access to emerging or breakthrough treatments These models are already in use globally. New Zealand, with its small scale and centralised health system, is well placed to adopt and lead in this space but doing so will require political will and cross-agency collaboration. One of the strongest criticisms of Pharmac is that its decision-making too often overlooks the most marginalised. Equity must not be treated as a footnote, it must be central to how decisions are made. Pharmac must evolve to meet New Zealand's healthcare needs, advocates say. Photo / Getty Images That means asking tough but necessary questions: are Māori and Pacific patients missing out? Are people in rural communities being reached? Are high-cost treatments for small groups, such as children with rare conditions, being given a fair assessment? True equity means seeing value not only in volume, but in fairness. We must move away from one-size-fits-all measures of utility and toward a model that recognises the value of treating the under-served, the isolated and the overlooked. Pharmac has made efforts to improve its equity lens, but these steps need to be embedded and expanded. This includes involving communities earlier in decision-making, co-designing criteria for assessment and setting explicit targets to reduce access gaps. If there is one thing Pharmac must urgently regain, it is public trust. Right now, too many New Zealanders feel shut out of its processes, confused by its rationale and left behind by its pace. Trust won't be rebuilt through a communications campaign. The Pharmac chair, Paula Bennett, is pushing through some important reforms which require a fundamental shift in how Pharmac relates to the people it serves. That means: ● Transparent processes that clearly explain what's funded and why ● Better engagement with patients, clinicians, researchers, and advocacy groups ● A willingness to admit when the system isn't working and to try new things The leadership of new CEO McMurtry offers an opportunity to reset that relationship. Her described strengths, quiet achievement, systems thinking, and clinical experience, will need to be paired with openness, boldness, and humility. It's encouraging to see the appointment of Dr Dale Bramley as CEO of Health New Zealand Te Whatu Ora. Bramley brings deep experience as a public health physician and former chief executive of the Waitematā District Health Board, along with a strong understanding of the health system from both clinical and leadership perspectives. Dr Dale Bramley has been appointed CEO of Health New Zealand Te Whatu Ora, bringing extensive public health and leadership experience to the role. Photo / Dean Purcell His appointment provides a valuable opportunity to strengthen alignment between Health New Zealand Te Whatu Ora and Pharmac. As the country moves towards integrated care as the national model, our approach to funding medicines must also evolve, recognising the role modern medicines play in improving patient outcomes and driving overall system efficiency. Pharmac's future must align with where the health system is heading: more integrated, more proactive, more preventive. Medicines that enable self-management, support digital care, or reduce reliance on acute services are now core to how we deliver better outcomes. Health systems globally are shifting from volume to value. New Zealand must do the same. That requires moving beyond simple funding silos and embracing joined-up thinking, where medicine access is seen as a strategic investment, not just a cost centre. Pharmac has a unique role to play in this shift. But to fulfil it, the agency must move from cautious gate keeping to confident leadership. It must be willing to challenge legacy assumptions and champion bold ideas that better serve the public good. The real test is whether it can lead to a smarter, fairer, more compassionate approach to medicine access – one that reflects the realities of modern New Zealand, embraces equity, and evolves as science and society change. The opportunity is real. With the right leadership, the right frameworks and the courage to think differently, Pharmac can become not just a funding body but a force for health transformation. But that will take more than good intentions. It will require bold decisions, structural reform and a clear commitment to doing things differently. Tinkering at the edges won't cut it. The time for real change is now. Ultimately, Pharmac's legacy won't be defined by how tightly it managed its budget. It will be judged by how well it met the health needs of its people.
